Navigation Links
Public not so sure 'personalized medicine'

Ordinary people worry about the extra, and often burdensome, responsibilities which could come with scientists promises of personalised medicine, according to evidence to be presented at a major two-day showcase of groundbreaking social science research into the whole field of genomics, funded by the Economic and Social Research Council (ESRC).

The event - Genomics and Society: Todays Answers, Tomorrows Questions is taking place in London on Thursday 25 and Friday 26 October 2007. This landmark gathering brings together policymakers, researchers and natural scientists with what is becoming the worlds largest concentration of social scientific research in this field - the ESRC Genomics Network (EGN) (See Notes for Editors).

Topics as diverse as plant and animal genetics, embryonic stem cell research, genetic databases, and the potential for huge advances in medicine, physical health and psychiatry are on the agenda. Regulation and ethics are also key focuses of attention, including research highlighting challenges faced by policymakers seeking to balance animal welfare against scientific productivity. And a study of four of the top ten Indian pharmaceutical firms reveals that many of the scientists who left for technologically more advanced regions of the world are now returning, bringing with them new skills and expertise from the west.

Peoples views on the use of genetic testing to prescribe and develop drugs, which has been seen as a technology that will accentuate the move towards individualisation of healthcare, were the focus of work led by Professor Brian Wynne, associate director of Cesagen - one of three research centres in the Network, and based at the universities of Lancaster and Cardiff.

Professor Wynne and Elisa Pieri used focus groups to get the opinions of hard-to-reach sections of the public, such as senior citizens, young people and parents of young children, as well as members of some ethnic communities in the north-west of England.

They found strong concerns about the increased, and often burdensome, levels of responsibility for people that would come from the being able to discover that they were susceptible to, or had early signs of, particular diseases, and about the necessary genetic testing it entails.

Professor Wynne said: Contrary to much of what is written and said about personalised medicine, members of the public highlighted how such promised options would impact and place strains on their families and relatives, as well as potentially lead to stigmatisation.

They were worried that it would limit their access to key services, such as insurance, mortgages, some medical coverage, and potentially even impact on their employment opportunities.

People also felt that individuals social and financial status would play a role in whether certain changes in lifestyles and treatments, suggested as a result of testing, could really be achieved. As Professor Wynne underlined: It is the credibility of the promises which drive such prospective innovations, and the real social conditions of their enactment, that are questions which government, industry and science need to take seriously as public policy issues.

Professor Steve Yearley, director of the Networks Genomics Policy and Research Forum said: This landmark event, marking the Networks transition to a new five-year phase of funding, gives the opportunity for a cross-fertilisation of ideas and healthy debate on the past, present and future roles of genomics in society.


Contact: Danielle Moore
Economic & Social Research Council

Related medicine news :

1. Controversial deal on public access of the human genome map
2. Defibrillators In Public Places Will Help Cardiac Patients
3. WHO To Support Public Health Threats
4. Public Defibrillators Found To Improve Survival Rate
5. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
6. WHO Steps Up To Create A Public Awareness About The Consequences Of Exposure To Radon
7. Disaster Planning Guide From Harvard Health Publications
8. India to maintain Public domain Registry database of clinical trials conducted in India.
9. Smoking Ban Believed To Enjoy Widespread Public Acceptance In Scotland
10. Evidences that Better Health Care Facility is Offered By Public Hospitals.
11. UK public misled over downgrading cannabis: Govt
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: